Floatz logo

Tas-102

Transitional Cell Cancer of the Renal Pelvis and Ureter

Cardiff UniversityunclassifiedPhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Transitional Cell Cancer of the Renal Pelvis and Ureter cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Nagoya University
Phase 3BBB
Carboplatin
Cardiff University
Phase 3BBB
VINBLASTINE
University of Southern California
Phase 3BBB
METHOTREXATE
University of Southern California
Phase 3BBB
FILGRASTIM
Tulane University Health Sciences Center
Phase 2BBB

View all 24 →

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Renal Cell CancerDormant
BB
Indicative ·
68 / 100
View asset →
Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, Islet CellDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →